The relative stability of the Brazilian economy and the large amount of public funds earmarked for the national health budget have sparked the interest of the pharmaceutical industry.
In Brazil, this can be divided into four different groups: research-based; foreign generics; local branded copies without interchangeability (known as similares); and government-owned pharmaceutical industries.
The Brazilian government is the largest player in the market, controlling 17 industries and the regulator (responsible for marketing approvals, pharmacovigilancy and price controls). It is also the country’s largest client. This unique combination has fostered the development of public private partnerships (PPPs) in the pharmaceutical industry, diverting the statutory intent of the law on PPPs.
When the law was enacted, its purpose was to implement PPPs to allow public services to be explored by private companies by means of concessions. Article 2 allowed for an ‘administrative concession’. A private company is hired to assume several public service obligations on behalf of a government entity.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.